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INTRODUCTION: The electron transport chain (ETC) in mitochondria functions to produce
energy in the form of adenosine triphosphate (ATP). Defects in the mitochondrial or nuclear
DNA that codes for components of the ETC lead to mitochondrial disorders (MTDs). MTDs are
multi-system conditions affecting the heart, muscles, and especially brain. The endocrine system
is commonly affected in MTDs, and diabetes and hyperglycemia are established secondary
diagnoses. Rates of non-iatrogenic hypoglycemia have not been studied in individuals with
MTDs. This study aims to investigate the frequency of hypoglycemia in patients with MTDs.
METHODS: Individuals diagnosed with a ‘definite’ or ‘probable’ MTD according to the
modified Walker criteria at The University of Texas, Mitochondrial Center of Excellence were
included in this study. Exclusion criteria included diagnosis of diabetes or adrenal
insufficiency or past or present use of hydrocortisone or prednisone. Patient charts were
reviewed retrospectively for blood glucose values. Individuals with at least two values were
recorded. Patients were classified as neonatal (≤28 days of life) or non-neonatal (>28 days of
life) at the time of measurement. Data analysis included descriptive statistics, mixed-model
regression, and two-sample tests of proportion. All data analysis was done using Stata® (v.13,
College Station, TX). Statistical significance was assumed at p<0.05.
RESULTS: Of the 116 patients included in this study, 22 (18.97%) experienced at least one
episode of hypoglycemia. This is significantly higher (p<0.05) than the 6% non-diabetic,
general population rate of hypoglycemia. Neonatal readings were also found to be 30mg/dL
lower than non-neonatal readings, on average, a significant difference (p<0.05).
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CONCLUSION: Patients with MTD are more likely to experience hypoglycemia compared to
the general population with especially low blood glucose readings during the neonatal period.
This demonstrates hypoglycemia may be contributing to the high rate of neurological symptoms
reported in MTDs and supports that MTDs should be on the differential diagnosis in cases of
hypoglycemia, especially during the neonatal period. Additional and earlier monitoring of blood
glucose could reduce negative outcomes such as decreased cognitive outcome, developmental
delays, seizures, or brain damage in patients with MTDs.
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INTRODUCTION

Mitochondria are organelles that engage in symbiotic relationships with eukaryotic cells:
mitochondria provide energy in the form of adenosine triphosphate (ATP) for the cells in
exchange for nutrients and proteins.1 Mitochondria are constructed from proteins coded for by
mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). The vast majority of ATP generated
by mitochondria is created through the electron transport chain (ETC), a series of components
that facilitate the exchange of electrons from chemical donors to chemical acceptors via
reduction-oxidation reactions.2 When the ETC malfunctions, ATP yield decreases significantly
leading to systemically low energy levels and multisystem malfunction. ETC dysfunction can be
caused by errors in either mtDNA or nDNA due to both contributing to the structural
composition of mitochondria. However, the majority of cases of ETC dysfunction are caused by
mtDNA mutations.3 Individuals with ETC dysfunction are referred to clinically as having a
mitochondrial disorder (MTD).1
MTDs affect a multitude of organ systems due to systemically low levels of ATP. The
heart, muscle, and brain are frequently affected tissues. Hallmark features of MTDs include
depletion of mitochondrial material, ragged red fibers in the muscles, strokes, lactic acidosis,
neuropathy, epilepsy, and encephalomyopathy.1 Prevalence of MTDs is known to be 1/4,3003,
but because of the variable expressivity in these conditions, diagnosis can be complicated.
Unlike other medical settings where genetic testing is able to give etiological information, this is
not necessarily the case with MTDs. Only a small portion of the genetic etiologies of these
conditions are understood at this time1, and in some cases, genetic yield is as low as 5%.4
Genetic information is most useful when considered in combined with other MTD symptoms.
The modified Walker criteria are a set of guidelines using a combination of clinical,
1

histological, enzymological, functional, and metabolic criteria in addition to genetic information
to diagnose MTD as ‘definite’, ‘probable’, or ‘possible’.4 Clinical presentations can sometimes
be separated into specific mitochondrial syndromes such as mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes (MELAS); myoclonic epilepsy with ragged red fibers
(MERRF); and neuropathy, ataxia, and retinitis pigmentosa (NARP). However, if the clinical
presentation does not fit a specific mitochondrial syndrome, the patient may remain in an
unspecified MTD category.1 Despite these differences in presentation, MTDs consistently cause
symptoms in systems requiring high loads of ATP such as the nervous and endocrine systems.1
The nervous system is the most frequently affected system, and forty-five percent of
children with MTDs demonstrate neurological symptoms.1 Similarly, endocrine system-related
symptoms (e.g., hypothyroidism, hypoparathyroidism, adrenal insufficiency, and diabetes) are
commonly found in these individuals, specifically diabetes.1,5 Mitochondria and their ATP
production in pancreatic islet β-cells are vital to the secretion of insulin in response to glucose
stimulation.6 This balance is compromised in patients with MTD and leads to the 22.3%
prevalence of diabetes and concomitant hyperglycemia in patients with MTDs.5 In addition to
hyperglycemia, patients with MTDs and diabetes who manage their diabetes with insulin are
known to experience iatrogenic hypoglycemia.7,8
Unlike hyperglycemia, non-iatrogenic hypoglycemia, another sign of endocrine
dysfunction, has not been well-documented in patients with MTDs. One case report described
three unrelated individuals with MTDs who had hypoglycemia as their only presenting feature9.
Otherwise, this correlation has not been studied. A recent study found the non-diabetic
population rate of hypoglycemia to be 6%10, and learning whether the rate in the MTD
population is significantly different or not is important due to the serious complications that can
results from hypoglycemia. These complications can be divided into two categories: 1)
2

neurogenic, which affect the autonomic nervous system and range from sweating and shakiness
and 2) neuroglycopenic, which affect the central nervous system, are much more severe, and can
lead to severe cognitive impairment.11,12 Episodes of hypoglycemia that occur during periods of
critical brain development are particularly damaging, and 25-50% of patients with neonatal
hypoglycemia have developmental delay.12 If MTDs do increase rates of hypoglycemia, the
related complications may, in turn, be contributing to the high rate of children with MTDs
having neurological symptoms.1 This retrospective chart review aimed to determine how the
frequency of hypoglycemia in a cohort of patients with MTDs without diabetes compared to the
general population rate of 6.0%.10
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METHODS

This study followed all regulations established by the Institutional Review Board of the
University of Texas at Houston Health Science Center (HSC-MS-09-0057). The University of
Texas, Mitochondrial Center of Excellence (UTMCE) patient database was used for this
retrospective chart review.
Data Collection
The electronic medical records (EMR) for patients seen at the UTMCE between
November 1997 and December 2018 were reviewed for those who had genetic testing to
determine the etiology of their MTD. They were then filtered for those who met ‘definite’ or
‘probable’ MTD diagnosis based on the modified Walker criteria.4 The charts for patients
meeting these criteria were systematically reviewed for measurements of serum glucose (SG)
recorded in milligrams/deciliter (mg/dL) either from clinic-requested labs or inpatient testing at
Children’s Memorial Hermann Hospital. Other information abstracted from the EMR included
demographics (i.e., sex, ethnicity, place of residence); the patient’s mitochondrial syndrome if
known; and whether the patient’s pathogenic variant is in the mtDNA, nDNA, or is unknown.
Patients were separated into one of 12 categories based on their mitochondrial syndrome.
Patients included in this study fell within the categories: combined oxidative phosphorylation
deficiencies (COXPD), depletion syndrome, Kearns-Sayre syndrome, Leigh syndrome,
MELAS, MERRF, MNGIE, NARP, an MTD plus another diagnosed condition (mito+), or an
unspecified MTD.
Exclusion Criteria
Patients were excluded from the study if they had a medical condition known to
influence SG either through its natural history or treatment, such as diabetes and adrenal
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insufficiency, or if the patient had past or present use of steroids (i.e., hydrocortisone and
prednisone). Patients with fewer than two SG measurements were also excluded. Any values
greater than 500mg/dL were excluded due to questionable reliability of the glucometer above
this cutoff. Any patient meeting one or more of the exclusion criteria was removed from the
study.
Data Classification
SG measurements were categorized as neonatal or non-neonatal depending on if the
patient was within the first 28 days of life or older than 28 days of life at the time of the
measurement. For this study, we defined hypoglycemia in the neonatal period as SG less than or
equal to 45mg/dL and hypoglycemia in the post-neonatal period as SG less than or equal to
60mg/dL. A more stringent cutoff for neonatal hypoglycemia than the 55-60 mg/dL previously
suggested12 was used as it is difficult to distinguish the difference between iatrogenic
hypoglycemia and post-birth-transitional hypoglycemia. To facilitate the visualization of trends
toward hypoglycemia, a category of low normal SG was defined as measurements up to
10mg/dL higher than hypoglycemia in the respective age groups (i.e., neonatal and non-neonatal
low normal SG ranged from 46-50mg/dL inclusive and 61-70mg/dL inclusive, respectively).
Hyperglycemia in any age group was defined as SG greater than or equal to 200mg/dL. This is
the cutoff for hyperglycemia following the administration of an oral glucose tolerance test7. This
stringent value was used to denote measurements that are truly abnormally high.
Data Analysis
This cohort was evaluated using descriptive statistics. Categorical data were described
using frequencies and percentages, and medians with interquartile ranges were used to describe
continuous variables. Contingency tests, such as Chi2 and Fisher’s Exact, were used to compare
categorical variables across groups. Additional statistical analysis between groups included a
5

random effects regression models, a mixed-effects regression analysis group, and two-sample
tests of proportion. All data analysis was done using Stata® (v.13, College Station, TX).
Statistical significance was assumed at p<0.05.
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RESULTS

At the time of data collection, the UTMCE patient database contained 799 patients. Two
hundred sixty-three had undergone genetic testing, and of those, 168 met the criteria of having a
‘definite’ or ‘probable’ MTD based on the modified Walker criteria.4 After excluding patients
with a diagnosis of diabetes or adrenal insufficiency, past or current use of hydrocortisone or
prednisone, or fewer than two SG measurements, 116 patients were included in the study. These
patients had a combined total 1,787 SG measurements.
Population Demographics and Serum Glucose Measurements
In the cohort, 60/116 (51.72%) were female. The average age was 11.8 years (range=0
days–65years). The majority of the patients reported Caucasian ethnicity (73/116, 62.93%). The
most common mitochondrial syndromes were depletion syndrome (11.21%), Leigh syndrome
(24.14%), and MELAS (10.34%). There were eight patients in the mito+ category. Nearly 82%
of the patients had a pathogenic mutation found with most being in the mtDNA (51/116,
42.97%). A total of 1,787 SG readings were collected with an average of 15.41 readings per
patient. Of the 116 patients, nine (7.76%) had SG drawn during the neonatal period with
99/1,787 (5.54%) total neonatal readings. All 116 patients collectively contributed to the
1,688/1,787 non-neonatal readings (94.46%). Patient demographics can be found in Table 1, and
SG measurement information can be found in Table 2.
Statistical Analysis
Of the total 1,787 SG readings collected, 51/1,787 (2.85%) were hypoglycemic. The
majority of readings (95.86%) were either normal or low normal, and 23/1,787 (1.29%) were
hyperglycemic (Table 2, Figure 1). The neonatal cohort was separated for individual analysis,
and the remaining cohort (i.e., non-neonatal cohort) was also analyzed independently. The
neonatal cohort had 17/99 (17.17%) hypoglycemic, 15/99 (15.15%) low normal, and 67/99
7

Patient Demographics
Category

n (%)

Sex
Female

60 (51.72)

Male

56 (48.28)

Ethnicity
African American

5 (4.31)

Asian

2 (1.72)

Hispanic

14 (12.07)

White

73 (62.93)

Other

18 (15.52)

Unknown

Depletion Syndrome
Kearns-Sayre Syndrome

Hypoglycemia

Hyperglycemia

0.210

0.487

0.391

0.789

0.423

0.780

0.356

0.637

3 (2.59)
13 (11.21)
4 (3.45)

Leigh Syndrome

28 (24.14)

MELAS

12 (10.34)

MERRF

2 (1.72)

MNGIE

1 (0.86)

NARP

2 (1.72)

Mitochondrial Disorder+

8 (6.90)

Unspecified

p-value

4 (3.45)

Mitochondrial Condition
COXPD

p-value

43 (37.07)

Pathogenic Mutation
mitoDNA

51 (43.97)

nDNA

21 (18.10)

Unknown

44 (37.93)

Total n=116
*Mitochondrial Disorder+ = meeting the Walker Criteria diagnosis of mitochondrial disorder +
a second diagnosis including: dopa dystonia (2), Friedreich’s ataxia (1), malignant hyperthermia
(1), multiple sclerosis (1), partial ornithine carbamoyltransferase (1), spondyloepimetaphyseal
dwarfism (1), and a 651kb interstitial deletion on chromosome 22 (1).
Table 1: Patient Demographics
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Summary of Number of Blood Glucose Measurements
Category

n (%)

Range

15.41
8.5

2–99

Recurrence (%)

Frequency (%)

p-value

Numbers Per Patient
Mean
Median
Whole Cohort Totals
Hypoglycemia
Low Normal
Normal

51 (2.85)
97 (5.43)
1,616 (90.43)

1–11

33.36

1.1–40

Hyperglycemia

23 (1.29)

1–6

41.67

1.1–50

2–11

100

8.33–19.05

1–9

17.76

1.1–40

1–6

41.67

1.1–50

Total n=1,787
Totals by Age
Hypoglycemia
†Neonatal Cohort Low Normal
(n=9) Normal
Hyperglycemia
Hypoglycemia
Non-Neonatal Cohort Low Normal
(n=107) Normal
Hyperglycemia

17 (17.17)
15 (15.15)
67 (67.68)

p<0.05*
p<0.05**

0 (0.00)
Total n=99 (5.54)
34 (2.01)
82 (4.86)
1,549 (91.77)
23 (1.36)

Total n=1,688 (94.46)
*Between rate of neonatal hypoglycemia and rate of non-neonatal hypoglycemia in this study by Chi2 and mixed-effect regression model
**Between rate of neonatal hypoglycemia and rate of non-diabetic hypoglycemia10
†
Neonatal = ≤28 days of life
Table 2: Summary of Number of Blood Glucose Measurements
9

Figure 1: Glucose Values for Each Study Subject

(67.68%) normal measurements (Table 2, Figure 2). There was no neonatal hyperglycemia. The
non-neonatal cohort had 34/1,688 (2.01%) hypoglycemic, 82/1,688 (4.86%) low normal,
1,549/1,688 (91.77%) normal, and 23/1,688 (1.36%) hyperglycemic SG measurements (Table 2,
Figure 2).
The median SGs were calculated per patient, and when these values were averaged
across the whole patient cohort, the mean was 90.32mg/dL (range=66–149.5mg/dL) (Table 3).
The minimum and maximum values for each patient were also averaged across the cohort and
can be found in Table 3. Similar calculations were done for the neonatal and non-neonatal
cohorts and can also be found in Table 3.
10

Summary of Blood Glucose Values (mg/dL)
Category

n

Range

90.32

66–149.5

70.64

14–108

135.36

67–433

79.33

68–86

29.00

14–43

204.00

156–257

90.62

66–149.5

71.74

29–108

133.54

67–433

Total Readings

Averages
Median
Whole Cohort
Low
(n=116)
High

1,787

Averages by Age
†Neonatal

Median
Cohort
Low
(n=9)
High

Median
Non-Neonatal Cohort
Low
(n=107)
High
†
Neonatal = ≤28 days of life

99

1,688

Table 3: Summary of Blood Glucose Values

Figure 2: Low Normal and Hypoglycemic Glucose Values (n=48)
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Of the 116 patients, 22/116 (18.97%) experienced at least one SG reading of
hypoglycemia as their lowest reading (Table 4.1). Just over 13% (3/22) of these readings were
neonatal (Table 4.2). An additional 26/116 patients (22.41%) experienced low normal SG as
their lowest reading (Table 4.1), three of which were neonatal (11.54%) (Table 4.2). The
remaining 68/116 patients (58.62%) had a normal SG as their lowest value (Table 4.1). In terms
of their highest readings, 12/116 patients (10.34%) experienced hyperglycemia (Table 4.1),
none of which were neonatal. The vast majority of patients had a normal value as their highest
SG (103/116, 88.79%), and only one patient had a low normal reading as their highest SG
(1/116, 0.86%) (Table 4.1).
Of the 22 patients with hypoglycemic measurements, one third experienced recurrent
hypoglycemia defined as more than one hypoglycemic reading (Table 2). 100% of neonatal
patients experienced repeat hypoglycemia (Table 2). Nearly half of patients with hyperglycemia
experience recurrence of these (Table 2). By number of readings, there was a statistically
significant increase in the rate of hypoglycemia in neonatal patients compared to non-neonatal
patients (17.17% versus 2.01%; p<0.05) (Table 2).
Using Chi2 analyses, there were no statistically significant differences in the likelihood
of having hypoglycemia depending on the patient’s sex (p=0.210), ethnicity (p=0.391), specific
diagnosis (p=0.423), or the location of their pathogenic mutation (p=0.356) (Table 1). There
were also no statistically significant differences with hyperglycemia and any of these categories
(sex p=0.487; ethnicity p=0.789; specific diagnosis p=0.780; location of pathogenic mutation
p=0.637) (Table 1). When assessing for time trends using a random effects regression model,
there was no statistically significant increases or decreases in SG readings for every day of life
gained (p=0.1403; 95% CI [-0.028]–0.199). Mixed-effects regression analysis showed a
statistically significant difference in the SG readings based on whether the individual was a
12

Table 4.1
Cross Tabulation of Blood Glucose Minimums and Maximums by Individual (Total)
Minimum Reading

Maximum Reading
Hypoglycemia

Low Normal

Normal

Hyperglycemia

Totals (%)

Hypoglycemia

0

0

18

4

22 (18.97)*

Low Normal

0

1

20

5

26 (22.41)

Normal

0

0

65

3

68 (58.62)

Hyperglycemia

0

0

0

0

0

0

1 (0.86)

103 (88.79)

12 (10.34)

116

Totals (%)

Table 4.2
Cross Tabulation of Blood Glucose Minimums and Maximums by Individual (†Neonatal)
Minimum Reading

Maximum Reading
Hypoglycemia

Low Normal

Normal

Hyperglycemia

Totals (%)

Hypoglycemia

0

0

3

0

3/116 (2.59)

Low Normal

0

0

3

0

3/116 (2.59)

Normal

0

0

3

0

3/116 (2.59)

Hyperglycemia

0

0

0

0

0

Totals (%)
0
0 (0)
9/116 (7.76)
0 (0)
*Denotes a statistically significant difference from general population values in non-diabetic patients10
†
Neonatal = ≤28 days of life

9/116

Tables 4.1 & 4.2: Cross Tabulation of Blood Glucose Minimums and Maximums by Individual (Total & Neonatal)
Non-neonatal hypoglycemia = ≤60mg/dL, low normal = 61-70mg/dL, normal = 71-199mg/dL, and hyperglycemia = ≥200mg/dL. Neonatal
hypoglycemia = ≤45mg/dL, low normal = 46-50mg/dL, normal = 51-199mg/dL, and hyperglycemia = ≥200mg/dL
13

neonate (p<0.05, 95% CI [-36.802]–[-23.715]) showing that on average, neonatal readings are
30mg/dL lower than non-neonatal readings. In this model, there was no difference in SG
readings for each year of life gained (p=0.222, 95% CI [-0.247]–0.057) or between females and
males (p=0.834, 95% CI [-3.755]–4.654). A two-sample test of proportion showed a statistically
significant increase in our cohort’s frequency of hypoglycemia (22/116=18.97%) compared to
the previously found population rate of hypoglycemia in patients without diabetes of 6.0%10
(p<0.05, 95% CI 0.43–0.186) (Table 2). A two-sample test of proportion also showed no
statistically significant difference in our cohort’s frequency of hypoglycemia compared to the
previously found population rate of hypoglycemia in patients with diabetes of 16.8%10
(p=0.8615, 95% CI [-0.065]–0.078).
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DISCUSSION

This study is the first to investigate the frequency of hypoglycemia in patients with
MTDs diagnosed by the modified Walker criteria.4 The vast majority of SG measurements
(95.86%) were either normal or low normal demonstrating the cohort experiences normal SG
the majority of the time. This was reiterated by the cohort-wide and non-neonatal averages of
mean, minimum, and maximum all being between 60mg/dL and 200mg/dL and, thus, higher
than either the cutoff for hypoglycemia or lower than the cutoff for hyperglycemia. While the
minimum and maximum for the neonatal cohort are both lower and higher than the normal
cutoffs, respectively, these are likely a reflection of a smaller sample size and possibly unknown
neonatal risk factors such as gestational age, maternal diabetes, and yet undiagnosed diabetes.12
Despite the majority of readings being normal, 18.97% of the cohort experienced
hypoglycemia (Table 4.1). This rate was similar to the 16.8% rate previously reported in
diabetic populations10 but is statistically higher than the 6.0% frequency found in a general, nondiabetic population.10 Recurrence of hypoglycemia was 33.36% in the full cohort and 100% in
neonates. The frequency of recurrence of hyperglycemia was unexpected considering the
population is void of individuals with diabetes, and rates of hyperglycemia are predicted to be
low in unaffected populations as these readings may be used to diagnose diabetes.7 However, as
this study is a retrospective chart review, the patients may be diagnosed with diabetes
eventually. Regardless, increased rates of both hypoglycemia and hyperglycemia demonstrate
endocrine malfunction.1
When considering individual readings, the frequency of hypoglycemia in neonates is
significantly increased compared to that in non-neonatal frequency. Neonatal SG is known to be
lower than that of older children and adults12, and this was reflected in this study by using a
lower threshold for hypoglycemia in neonates. Regardless, a 30mg/dL decrease still exceeds the
15

established difference in cutoffs and indicates neonates with MTD may be predisposed to
abnormally low hypoglycemia. However, other unknown neonatal risk factors may have played
a role in these levels.12
Recently, a study looking at a group of patients with Prader-Willi syndrome found
12.6% frequency of hypoglycemia in the neonatal population.13 Prader-Willi syndrome is also
commonly associated with endocrine dysfunction, and Harrington et al. suggested neonatal
hypoglycemia may play a role in the diminished neurological abilities of these patients.13 Our
population of non-diabetic patients with MTDs was three times more likely to experience
hypoglycemia than the non-diabetic general population.10 Additionally, neonates were
significantly more likely to experience SG readings 30mg/dL lower than their non-neonatal
counterparts. These findings supports the notion that endocrine malfunction may be one of the
first symptoms of MTD and may severely influence SG levels in neonates. Children with MTDs
may experience diminished neurocognitive abilities due to hypoglycemia in early life or later
undiagnosed hypoglycemia.1,13
Study Limitations
There are several inherent limitations to a retrospective chart review. Information
regarding whether the SG values were fasting or reactive was not available. Similarly, the nature
of the EMR made it difficult to ascertain the full course of treatment for the episodes of
hypoglycemia, making it impossible to determine if these occurrences would qualify as true,
clinical hypoglycemic episodes or if they are artifact hypoglycemia. Information regarding
when the patient may have started treatment for the symptoms of their disease was also not
available, and we are unable to say whether this influenced their SG readings. Because this
study is retrospective, patient outcomes, such as whether or not the patients develop diabetes,
are not known. Lastly, birth information, such as weight or gestational age, for neonatal patients
16

was not collected. Without this information, the possibility of neonatal hypoglycemia being due
to other neonatal risk factors12 cannot be eliminated.
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CONCLUSION

Based on the finding of 18.97% hypoglycemia in this non-diabetic, MTD population,
glucose monitoring for low SG values should become standard of care. These data also support
that endocrine malfunction may be one of the first symptoms of MTDs. Forty-five percent of
children with MTDs demonstrate neurological symptoms1, and this study demonstrates that it is
reasonable to consider at least a portion of those childrens’ symptoms may be due to aberrant
glucose values, particularly during critical brain development. MTDs should be on the
differential diagnosis in cases of hypoglycemia, particularly neonatal hypoglycemia. Thornton
et al. previously published recommendation for the monitoring of neonates with recurrent
episodes of hypoglycemia12, and this study demonstrates that analysis for MTD by modified
Walker criteria may be warranted in the presence of repeat neonatal hypoglycemia.
Additionally, very low hypoglycemia may be another indication warranting MTD analysis,
particularly if in the presence of repeat hypoglycemia. Identifying patients with MTD as early as
possible to avoid the serious neurological complications that can result from uncontrolled
glucose such as decreased cognitive abilities, developmental delay, seizures, or death is
important for best health outcomes. 11,12 Future longitudinal studies following patients from
birth with information regarding whether the SG readings are fasting or reactive would help
establish patterns throughout development and whether hypoglycemia leads to specific
complications in the future

18
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